We observed that patients with ER + PR + HER2 + BC bearing RRM2B amplifications had a significant decrease in OS (p = 0.0178, Figures 6C,E), with no difference in DFS (Figures 6D,F). The gene discussed is ERBB2; the disease is breast cancer.